Targeted treatments for fragile X syndrome

Journal of Neurodevelopmental Disorders

Volumn 3, Issue 3, 2011, Pages 193-210

  Berry Kravis, Elizabeth ^a   Knox, Andrew ^a   Hervey, Crystal ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autism; Dendritic translation; FMRP; Fragile X syndrome; GABA agonists; Metobotropic glutamate receptors; Signal transduction; Synaptic plasticity

Indexed keywords

EID: 80052347724     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1007/s11689-011-9074-7     Document Type: Article

References (146)

1. Adusei DC, Pacey LK, Chen D, Hampson DR. Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology. 2010; 59: 167-71.
2. Antar LN, Afroz R, Dictenberg JB, Carroll RC, Bassell GJ. Metabotropic glutamate receptor activation regulates fragile X mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J Neurosci. 2004; 24: 2648-55.
3. Aschrafi A, Cunningham BA, Edelman GM, Vanderklish PW. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc Natl Acad Sci USA. 2005; 102: 2180-5.
4. Awadalla P, Gauthier J, Myers RA, Casals F, Hamdan FF, Griffing AR, et al. Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. Am J Hum Genet. 2010; 87: 316-24.
5. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci. 2005; 6: 376-87.
6. Bakker CE, Oostra BA. Understanding fragile X syndrome: insights from animal models. Cytogenet Genome Res. 2003; 100: 111-23.
7. Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron. 2008; 60: 201-14.
8. Bear MF. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav. 2005; 4: 393-8.
9. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004; 27: 370-7.
10. Bear MF, Dolen G, Osterweil E, Nagarajan N. Fragile X: translation in action. Neuropsychopharmacology. 2008; 33: 84-7.
11. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature. 1993; 361: 315-25.
12. Berry-Kravis E, Ciurlionis R. Overexpression of fragile X gene (FMR-1) transcripts increases cAMP production in neural cells. J Neurosci Res. 1998; 51: 41-8.
13. Berry-Kravis E, Hicar M. Reduced cyclic AMP production in fragile X syndrome: cytogenetic and molecular correlations. Pediatr Res. 1995; 38: 638-43.
14. Berry-Kravis E, Potanos K. Pschopharmacology in fragile X syndrome-present and future. Ment Retard Dev Disabil Res Rev. 2004; 10: 42-8.
15. Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharm. 2006; 16: 525-40.
16. Berry-Kravis E, Abrams L, Coffey S, Hall D, Greco C, Gane L, et al. Fragile X-associated tremor/ataxia syndrome (FXTAS): clinical features, genetics and testing guidelines. Mov Disord. 2007; 22: 2018-30.
17. Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008a; 29: 293-302.
18. Berry-Kravis E, Lara R, Kim O-K, Sumis A, Wuu J. Characterization of potential outcome measures for future clinical trials in fragile X syndrome. J Autism Dev Disord. 2008b; 38: 1751-7.
19. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009; 46: 266-71.
20. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009; 46: 94-102.
21. Blackwell E, Zhang X, Ceman S. Arginines of the RGG box regulate FMRP association with polyribosomes and mRNA. Hum Mol Genet. 2010; 19: 1314-23.
22. Boccia JL, Roberts JE. Behavior and autonomic nervous system function assessed via heart period measures: the case of hyperarousal in boys with fragile X syndrome. Behav Res Meth Instrum Comput. 2000; 32: 5-10.
23. Bolduc FV, Bell K, Cox H, Broadie KS, Tully T. Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. Nat Neurosci. 2008; 11(10): 1143-5.
24. Brennan FX, Albeck DS, Paylor R. Fmr1 knockout mice are impaired in a leverpress escape/avoidance task. Genes Brain Behav. 2006; 5: 467-71.
25. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, et al. Microarray identification of FMRP associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001; 107: 477-87.
26. Brown M, Kronengold J, Gazula V-R, Chen Y, Strumbos JG, Sigworth FJ, et al. Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. Nat Neurosci. 2010; 13: 819-21.
27. Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther. 1997; 280: 1284-95.
28. Ceman S, Brown V, Warren ST. Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol Cell Biol. 1999; 19: 7925-32.
29. Chang S, Bray SM, Li Z, Zarnescu DC, He C, Jin P, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol. 2008; 4: 256-63.
30. Cheever A, Ceman S. Phosphorylation of FMRP inhibits association with Dicer. RNA. 2009; 15: 362-6.
31. Chen L, Yun SW, Seto J, Liu W, Toth M. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience. 2003; 120: 1005-17.
32. Chen LY, Rex CS, Babayan AH, Kramar EA, Lynch G, Gall CM, et al. Physiological activation of synaptic Rac>PAK (p-21 activated kinase) signaling is defective in a mouse model of fragile X syndrome. J Neurosci. 2010; 30: 10977-84.
33. Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci. 2005; 25: 8048-55.
34. Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ, et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci USA. 1997; 94: 5401-4.
35. Cornish K, Kogan C, Turk J, Manly T, James N, Mills A, et al. The emerging fragile X premutation phenotype: evidence from the domain of social cognition. Brain Cogn. 2005; 57: 53-60.
36. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell. 2001; 107: 489-99.
37. Darnell JC, van Dreische S, Zhang C, Mele A, Zang JB, Fak JJ, et al. HITS-CLIP identifies specific neuronal mRNA targets of translational repression by the fragile X mental retardation protein, FMRP. Keystone Symposia, Synapses: Formation, Function, and Misfunction, April 14, 2010. Snowbird, Utah.
38. D'Hulst C, Kooy RF. The GABAA receptor: a novel target for treatment of fragile X? Trends Neurosci. 2007; 30: 425-31.
39. D'Hulst C, De Geest N, Reeve SP, van Dam D, De Deyn PP, Hassan BA, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006; 1121: 238-45.
40. de Vries BB, Wiegers AM, Smits AP, Mohkamsing S, Duivenvoorden HJ, Fryns JP, et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet. 1996; 58: 1025-32.
41. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis. 2008; 31: 127-32.
42. Devys D, Lutz Y, Rouyer N, Bellocq JP, Mandel JL. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet. 1993; 4: 335-40.
43. Dockendorff TC, Su HS, McBride SM, Yang Z, Choi CH, Siwicki KK, et al. Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron. 2002; 34: 973-84.
44. Dolen G, Osterweil E, Shankaranarayana Rao BS, Smith GB, Auerbach BD, Chattarji S, et al. Correction of fragile X syndrome in mice. Neuron. 2007; 56: 955-62.
45. Drug Discovery: PAK Program. http://www. afraxis. com.
46. Du J, Wei Y, Liu L, Wang Y, Khairova R, Blumenthal R, et al. A kinesin singnaling complex mediate the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci USA. 2010; 107: 11573-8.
47. Erickson CA, Mullett JE, McDougle CJ. Open-label memantine in fragile X syndrome. J Autism Dev Disord. 2009; 39: 1629-35.
48. Erickson CA, Mullett JE, McDougle CJ. Brief report: Acamprosate in fragile X syndrome. J Autism Dev Disord. 2010a; 40: 1412-6.
49. Erickson CA, Stigler KA, Posey DJ, McDougle CJ. Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics. 2010b; 7: 258-63.
50. Erickson CA, Weng N, Weiler IJ, Greenough WT, Stigler KA, Wink LK, McDougle CJ. Open-label riluzole in fragile X syndrome. Brain Res. 2011. doi: 10. 1016/j. brainres. 2010. 10. 108.
51. Farzin F, Rivera SM, Hessl D. Brief report: Visual processing of faces in individuals with fragile X syndrome: an eye tracking study. J Autism Dev Disord. 2009; 39: 946-52.
52. Farzin F, Scaggs F, Hervey C, Hessl D, Berry-Kravis E. Feasibility, reliability and clinical validity of eye-tracking and pupillometry as an outcome measure for clinical trials in fragile X syndrome (FXS). J Autism Dev Disord. 2011 (in press).
53. Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST. FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol Cell. 1997; 1: 109-18.
54. Frisardi V, Solfrizzi V, Imbimbo PB, Capurso C, D'Introno A, Colacicco AM, et al. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr Alzheimer Res. 2010; 7(1): 40-55.
55. Gantois I, Vandesompele J, Speleman F, Reyniers E, D'Hooge R, Severijnen LA, et al. Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis. 2006; 21: 346-57.
56. Gibson JR, Bartley AF, Hays SA, Huber KM. Imbalance of neocortical excitation and inhibitionand altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J Neurophys. 2008; 100: 2615-26.
57. Goebel-Goody SM, Wallis ED, Li DV, Hall V, Royston S, Baum M, et al. 2010. Loss of striatal-enriched protein tyrosine phosphatase (STEP) reverses deficits in a fragile x syndrome mouse model. Program No. 452. 4. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience (online).
58. Gross C, Nakamoto M, Yao X, Chan C-B, Yim SY, Ye K, et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci. 2010; 30: 10624-38.
59. Grossman AW, Aldridge GM, Weiler IJ, Greenough WT. Local protein synthesis and spine morphogenesis: fragile X syndrome and beyond. J Neurosci. 2006; 26: 7151-5.
60. Hagerman PJ. The fragile X prevalence paradox. J Med Genet. 2008; 45: 498-9.
61. Hagerman RJ, Berry-Kravis E, Ono MY, Tartaglia N, Lachiewicz A, Kronk B, et al. Advances in the treatment of fragile X syndrome. J Pediatr. 2009; 123: 378-90.
62. Hayashi ML, Rao BS, Seo JS, Choi HS, Dolan BM, Choi SY, et al. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci USA. 2007; 104: 11489-94.
63. Hessl D, Tassone F, Loesch DZ, Berry-Kravis E, Leehey MA, Gane LW, et al. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet. 2005; 139: 115-21.
64. Hessl D, Cirdeiro L, Yuhas J, Campball A, Ornitz E, Berry-Kravis E, et al. Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. Am J Med Genet. 2008a; 153B: 545-53.
65. Hessl D, Tassone F, Cordiero L, Koldewyn K, McCormick C, Green C, et al. Brief report: Aggression and stereotypic behavior in males with fragile X syndrome-moderating secondary genes in a "single gene" disorder. J Autism Dev Disord. 2008b; 38: 184-9.
66. Hessl D, Maltas S, Hall S, Kaufmann W, Lachiewicz A, et al. 2010. Toward a fragile X behavior rating scale: the aberrant behavior checklist collaborative study. 12th International Fragile X Conference, 21 July 2010, Detroit, Michigan.
67. Heulens I, Kooy F. Fragile X syndrome: from gene discovery to therapy. Front Biosci. 2011; 16: 1211-32.
68. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA. 2002; 99: 7746-50.
69. Irwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, Larsen BP, et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet A. 2001; 98: 161-7.
70. Irwin SA, Idupulapati M, Gilbert ME, Harris JB, Chakravarti AB, Rogers EJ, et al. Dendritic spine and dendritic field characteristics of later V pyramidal neurons in the visual cortex of fragile X-knockout mice. Am J Med Genet. 2002; 111: 140-6.
71. Jacquemont S, Curie A, des Portes V, Berry-Kravis E, Hagerman RJ, Ramos F, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011; 3: 64ra1.
72. Jourdi H, Hsu YT, Zhou M, Qin Q, Bi X, Baudry M. Positive AMPA receptor modulating rapidly stimulates BDNF release and increases dendritic mRNA translation. J Neurosci. 2009; 29(8): 8688-97.
73. Kelley DJ, Davidson RJ, Elliott JL, Lahvis GP, Yin JC, Bhattacharyya A. The cyclic AMP cascade is altered in fragile X nervous system. PLoS ONE. 2007; 26: e931.
74. Knox A, Berry-Kravis E. Feasibility and reproducibility of the Tests of Attentional Performance for Children (KiTAP) in fragile X syndrome (FXS). Ann Neurol. 2009; 66: S108.
75. Koekkoek SK, Yamaguchi K, Milojkovic BA, Dortland BR, Ruigrok TJ, Maex R, et al. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines and attenuates cerebellar eyelid conditioning in fragile X syndrome. Neuron. 2005; 47: 339-52.
76. Kolasiewicz W, Kuter K, Wardas J, Ossowska K. Role of the metabotropic glutamate receptor subtype 1 in the Harmaline-induced tremor in rats. J Neural Transm. 2009; 116: 1059-63.
77. A receptor as a potential target for therapy of the fragile X syndrome. The 12th International Fragile X Conference, 22 July 2010, Detroit, Michigan.
78. Larson J, Jessen RE, Kim D, Fine AK, du Hoffman J. Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. J Neurosci. 2005; 25: 9460-9.
79. Larson J, Kim D, Patel RC, Floreani C. Olfactory discrimination learning in mice lacking the fragile X mental retardation protein. Neurobiol Learn Mem. 2008; 90: 90-102.
80. Lauterborn JC, Rex CS, Kramar E, Chen LY, Pandyarajan V, Lynch G, et al. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci. 2007; 27(40): 10685-94.
81. Lee A, Li W, Xu K, Bogert BA, Su K, Gao FB. Control of dendritic development by the Drosophila fragile X-related gene involves the small GTPase Rac1. Development. 2003; 130: 5543-52.
82. Levenga J, de Vrig FMS, Oostra BA, Willamson R. Potential therapeutic interventions for fragile X syndrome. Trend Mol Med. 2010; 16: 516-27.
83. Li J, Pelletier MR, Perez Velazquez JL, Carlen PL. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci. 2002; 19: 138-51.
84. Liu ZH, Chuang DM, Smith CB. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Neuropsychopharmacology. 2010; 25: 1-13.
85. Loesch DZ, Huggins RM, Bui QM, Epstein JL, Taylor AK, Hagerman RJ. Effect of the deficits of fragile X mental retardation protein on cognitive status of fragile X males and females assessed by robust pedigree analysis. J Dev Behav Pediatr. 2002; 23: 416-23.
86. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev. 2004; 10: 31-41.
87. Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, Musella A, et al. Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology. 2010; 35: 1500-9.
88. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet. 2008; 82: 477-88.
89. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a model of fragile X syndrome. Neuron. 2005; 45: 753-64.
90. McDonnell MN, Orekhov Y, Ziemann U. Suppression of LTP-like plasticity in human motor cortex by the GABAB receptor agonist baclofen. Exp Brain Res. 2007; 180: 181-6.
91. Miller LJ, McIntosh DN, McGrath J, Shyu V, Lampe M, Taylor AK, et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am J Med Genet. 1999; 83: 268-79.
92. Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, Jope RS, et al. Elevated glycogen synthase kinase-3 activity in fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology. 2009; 56: 463-72.
93. Mines MA, Yuskaitis CJ, Beurak E, Jope RS. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS ONE. 2010; 5: e9706.
94. Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron. 2003; 37: 417-31.
95. Morales J, Hiesinger PR, Schroeder AJ, Kume K, Verstreken P, Jackson FR, et al. Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron. 2002; 34: 961-72.
96. Muddashetty R, Bassell GJ. A boost in microRNAs shapes up the synapse. EMBO J. 2009; 28: 617-8.
97. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci. 2007; 16(27): 5338-48.
98. Muddashetty RS, Nalavadi VC, Gross C, Yao X, Warren ST, Bassell GJ. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation and mGluR signaling. Program No. 548. 2. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010 (online).
99. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci USA. 2007; 104: 15537-42.
100. Narayanan U, Nalavadi V, Nakamoto M, Thomas G, Ceman S, Bassell GJ, et al. S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. J Biol Chem. 2008; 283: 18478-82.
101. Nelson D. 2010. New models of FXS in the mouse to assess developmental effects of FMR1 Mutation. 12th International Fragile X Conference, 23 July 2010, Detroit, Michigan.
102. NIH (2009). Outcome measures for clinical trials in children with fragile X syndrome-Meeting Summary November 5 and 6, 2009. Bethesda Marriott, Pooks Hill, Bethesda, MD. http://rarediseases. info. nih. gov/ScientificConferences. aspx?PageID=5& ID=989.
103. Nimchinsky EA, Oberlander AM, Svoboda K. Abnormal development of dendritic spines in FMR1 knock-out mice. J Neurosci. 2001; 21: 5139-46.
104. Osterweil EK, Krueger DD, Reinhold K, Bear MF. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci. 2010; 30: 15616-27.
105. Owen R, Gordon-Weeks PR. Inhibition of glycogen synthase kinase 3beta in sensory neurons in culture alters filopodia dynamics and microtubule distribution in growth cones. Mol Cell Neurosci. 2003; 23: 626-37.
106. Pacey LK, Heximer SP, Hampson DR. Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol. 2009; 76: 18-24.
107. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell I, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010; 10: 91.
108. Park S, Park JM, Kim S, Kim JA, Shepard JD, Smith-Hicks CL, et al. Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3. 1 essential for mGluR-LTD. Neuron. 2008; 59: 70-83.
109. Paylor R. 2008. Pharmacological modification of behavioral responses in the fragile X mouse model. 11th International Fragile X Conference, 25 July 2008, St. Louis, Missouri.
110. Paylor R, Yuva-Paylor LA, Nelson DL, Spenser CM. Reversal of sensorimotor gating abnormalities in Fmr1 knockout mice carrying a human Fmr1 transgene. Behav Neurosci. 2008; 122: 1371-7.
111. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010; 466: 368-72.
112. Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J Neurosci. 2005; 25: 5087-95.
113. Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride S, Klann E, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci. 2010; 30: 694-702.
114. Shumbos JG, Brown M, Kronengold J, Polley DB, Kaczmerak LK. Fragile x mental retardation protein is required for rapid experience-dependent regulation of the potassium channel Kv3. 1b. J Neurosci. 2010; 30: 10263-71.
115. + currents by muscarinic and metabotropic glutamate receptors in immature rat hippocampus. J Physiol. 2007; 580: 411-22.
116. Spencer CM, Graham DF, Yuva-Paylor LA, Nelson DL, Paylor R. Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene. Behav Neurosci. 2008; 122: 710-5.
117. Steckler T, Oliveira AF, van Dyck C, van Craenendonck H, Mateus AM, Langloi X, et al. Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial water maze task. Behav Brain Res. 2005; 164: 52.
118. Subrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. Characterization and reversal of synaptic defects in the amygdale in a mouse model of fragile X syndrome. Proc Natl Acad Sci USA. 2010; 107: 11591-6.
119. Sullivan AK, Marcus M, Epstein MP, Allen EG, Anido AE, Paquin JJ, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod. 2005; 20: 402-12.
120. Sullivan K, Hooper S, Hatton D. Behavioral equivalents of anxiety in children with fragile X syndrome: parent and teacher report. J Intellect Disabil Res. 2007; 51: 54-65.
121. Tassone F, Hagerman RJ, Ikle DN, Dyer PN, Lampe N, Willemson R, et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet. 1999; 84: 250-61.
122. Tassone F, Hagerman RJ, Taylor AK, Mills JB, Harris SW, Gane LW, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet. 2000; 91: 144-52.
123. Turner G, Webb T, Wake S, Robinson H. Prevalence of fragile X syndrome. Am J Med Genet. 1996; 64: 196-7.
124. Utari A, Chonchaiya W, Rivera SM, Schneider A, Hagerman RJ, Faradz SM, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil. 2010; 115(5): 433-43.
125. Venkitaramani DV, Aldridge GM, Kao D-I, Morris DR, Weiler I, Greenough WT. 2010. Rescue of fragile X syndrome metabolic and behavioral phenotypes by lithium. Program No. 757. 12. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience (online).
126. Ventura R, Pascucci T, Catania MV, Musumeci SA, Puglisi-Allegra S. Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex. Behav Pharmacol. 2004; 15: 433-42.
127. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991; 65: 905-14.
128. Volk LJ, Pfeiffer BE, Gibson JR, Huber KM. Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. J Neurosci. 2007; 27: 11624-34.
129. Wang H, Wu LJ, Zhang F, Zhou M. Roles of calcium-stimulated adenylyl cyclase and calmodulin-depebdent protein kinase IV in the regulation of FMRP by group I metabotropic glutamate receptors. JNeurosci. 2008a; 28: 4385-97.
130. Wang H, Wu LJ, Kim SS, Lee FJ, Gong B, Toyoda H. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron. 2008b; 59: 634-47.
131. Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics. 2010a; 7: 264-74.
132. Wang H, Kim SS, Zhuo M. Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent α-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization. J Biol Chem. 2010b; 285: 21888-901.
133. Wang L, Hagerman R, Rathmell B, Wang P, Berry-Kravis E. 2010c. Arbaclofen treatment is associated with global behavioral improvement in fragile X syndrome (FXS): results of a randomized, controlled phase 2 trial. 2010 Annual Meeting of the Society for Developmental and Behavioral Pediatrics, Sept 12, 2010, Boston, Massachusetts.
134. Waung MW, Huber KM. Protein translation in synaptic plasticity: mGluR-LTD, fragile X. Curr Opin Neurobiol. 2009; 19: 319-26.
135. Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci USA. 1997; 94: 5395-400.
136. Weiler IJ, Spangler CC, Klintsova AY, Grossman AW, Kim SH, Bertaina-Anglade V, et al. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc Natl Acad Sci USA. 2004; 101: 17329-30.
137. Weng N, Weiler IJ, Sumis A, Berry-Kravis E, Greenough WT. Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am J Med Genet. 2008; 147B: 1253-7.
138. Westmark CJ, Malter JS. FMRP mediates mgluR5-dependent translation of amyloid precursor protein. PLoS Biol. 2007; 5: e52.
139. Westmark CJ, Westmark PR, Hays SA, Hervey CM, Salamat MS, Stein KM, et al. 2010. Reversal of fragile X phenotypes by manipulation of APP/Ab levels. Society for Neuroscience 17 November 2010, San Diego, California.
140. Yan QJ, Asafo-Adjei PK, Arnold HM, Brown RE, Bauchwitz RP. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav. 2004; 3: 337-59.
141. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005; 49: 1053-66.
142. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol. 2010; 79: 632-46.
143. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell. 2003; 112: 317-27.
144. Zhang L, Alger BE. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci. 2010; 30: 5724-9.
145. Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, et al. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell. 2001; 107: 591-603.
146. Zhang Y, Venkitaramani DV, Gladding CM, Zhang Y, Kurup P, Molnar E, et al. The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J Neurosci. 2008; 28: 10561-6.